JP2012528845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528845A5 JP2012528845A5 JP2012513685A JP2012513685A JP2012528845A5 JP 2012528845 A5 JP2012528845 A5 JP 2012528845A5 JP 2012513685 A JP2012513685 A JP 2012513685A JP 2012513685 A JP2012513685 A JP 2012513685A JP 2012528845 A5 JP2012528845 A5 JP 2012528845A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- form according
- microparticles
- eudragit
- melt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000011859 microparticle Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 5
- 229920001577 copolymer Polymers 0.000 claims 4
- 239000010419 fine particle Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000003402 opiate agonist Substances 0.000 claims 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229960001410 hydromorphone Drugs 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 229960001631 Carbomer Drugs 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 229920003164 Eudragit® NE 40 D Polymers 0.000 claims 1
- 229920003155 Eudragit® RL 100 Polymers 0.000 claims 1
- 229920003156 Eudragit® RL PO Polymers 0.000 claims 1
- 229920003159 Eudragit® RS 100 Polymers 0.000 claims 1
- 229920003160 Eudragit® RS PO Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 Fentanyl Drugs 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N Tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N Tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- 229960004380 Tramadol Drugs 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229930014694 morphine Natural products 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- 230000003364 opioid Effects 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920001888 polyacrylic acid Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001624 sedative Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229960005126 tapentadol Drugs 0.000 claims 1
- 230000002936 tranquilizing Effects 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0909680.1A GB0909680D0 (en) | 2009-06-05 | 2009-06-05 | Dosage form |
GB0909680.1 | 2009-06-05 | ||
PCT/GB2010/050948 WO2010140007A2 (fr) | 2009-06-05 | 2010-06-07 | Forme pharmaceutique |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012528845A JP2012528845A (ja) | 2012-11-15 |
JP2012528845A5 true JP2012528845A5 (fr) | 2013-07-25 |
JP5635082B2 JP5635082B2 (ja) | 2014-12-03 |
Family
ID=40936947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012513685A Expired - Fee Related JP5635082B2 (ja) | 2009-06-05 | 2010-06-07 | 剤形 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9814679B2 (fr) |
EP (1) | EP2437729B1 (fr) |
JP (1) | JP5635082B2 (fr) |
KR (1) | KR101816130B1 (fr) |
CN (2) | CN102481260A (fr) |
AU (1) | AU2010255502B2 (fr) |
BR (1) | BRPI1012004A2 (fr) |
CA (1) | CA2764517C (fr) |
EA (1) | EA022801B1 (fr) |
ES (1) | ES2713957T3 (fr) |
GB (1) | GB0909680D0 (fr) |
IL (1) | IL216748A0 (fr) |
MX (1) | MX2011012929A (fr) |
MY (1) | MY173629A (fr) |
NZ (1) | NZ596879A (fr) |
SG (2) | SG176304A1 (fr) |
WO (1) | WO2010140007A2 (fr) |
ZA (1) | ZA201109221B (fr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
EP2957281A1 (fr) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Systeme de liberation a base de polymere |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
EP2301526B1 (fr) | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Système de libération contrôlée de morphine |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
WO2008148798A2 (fr) | 2007-06-04 | 2008-12-11 | Egalet A/S | Compositions pharmaceutiques à libération contrôlée pour un effet prolongé |
CN101801350A (zh) * | 2007-08-13 | 2010-08-11 | 阿巴斯迪特宁医药有限公司 | 抗滥用药物、使用方法和制备方法 |
EP2249811A1 (fr) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Forme posologique pharmaceutique |
EP2273983B1 (fr) | 2008-05-09 | 2016-07-20 | Grünenthal GmbH | Procédé de préparation d'une formulation de poudre intermédiaire et d'une forme galénique solide finale en utilisant une étape de congélation par pulvérisation |
WO2010089132A1 (fr) | 2009-02-06 | 2010-08-12 | Egalet A/S | Composition à libération immédiate résistant à une maltraitance par prise d'alcool |
NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
PL2456424T3 (pl) | 2009-07-22 | 2013-12-31 | Gruenenthal Gmbh | Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania |
PL2456427T3 (pl) | 2009-07-22 | 2015-07-31 | Gruenenthal Gmbh | Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu |
EA201291211A1 (ru) * | 2010-05-10 | 2013-05-30 | Эро-Селтик С.А. | Фармацевтические композиции, содержащие гидроморфон и налоксон |
CN103002882B (zh) | 2010-05-10 | 2016-03-02 | 欧洲凯尔特公司 | 不含活性剂之颗粒及包含其之片剂的制备 |
US9901540B2 (en) | 2010-05-10 | 2018-02-27 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
AU2011297901B2 (en) | 2010-09-02 | 2014-07-31 | Grunenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
MX2013002293A (es) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico. |
WO2012061779A1 (fr) * | 2010-11-04 | 2012-05-10 | Abbott Gmbh & Co. Kg | Formulations de médicaments |
EP2635247B1 (fr) | 2010-11-04 | 2016-12-14 | AbbVie Inc. | Procédé de fabrication de comprimés monolithiques |
GB201020895D0 (en) * | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
UA109301C2 (uk) * | 2010-12-28 | 2015-08-10 | Комбінація опіоїдного агоніста й опіоїдного антагоніста в лікуванні хвороби паркінсона | |
PE20141638A1 (es) | 2011-07-29 | 2014-11-22 | Gruenenthal Chemie | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
WO2013038267A1 (fr) * | 2011-09-16 | 2013-03-21 | Purdue Pharma L.P. | Formulations pharmaceutiques inviolables |
WO2013050539A2 (fr) * | 2011-10-06 | 2013-04-11 | Grünenthal GmbH | Forme pharmaceutique orale inviolable comprenant un agoniste opioïde et un antagoniste opioïde |
KR20140096062A (ko) * | 2011-11-17 | 2014-08-04 | 그뤼넨탈 게엠베하 | 약리학적 활성 성분, 오피오이드 길항제 및/또는 혐오제, 폴리알킬렌 옥사이드 및 음이온성 중합체를 포함하는 탬퍼-저항성 경구 약제학적 투여형 |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
EA201401139A1 (ru) * | 2012-04-18 | 2015-03-31 | Грюненталь Гмбх | Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
WO2014011830A1 (fr) | 2012-07-12 | 2014-01-16 | Mallinckrodt Llc | Compositions pharmaceutiques de dissuasion d'abus à libération prolongée |
CA2795324C (fr) * | 2012-11-09 | 2015-07-14 | Purdue Pharma | Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
JP6445537B2 (ja) * | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形 |
MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
CA2919892C (fr) * | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Comprime extrude anti-abus a liberation immediate |
KR102194174B1 (ko) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
WO2015071248A1 (fr) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Composition pharmaceutique à libération prolongée, non détournable, contenant du tapentadol |
JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (fr) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Comprimé extrudé anti-abus à libération prolongée |
CA2934078C (fr) * | 2013-12-17 | 2019-08-06 | Pharmaceutical Manufacturing Research Services, Inc. | Pilule extrudee a liberation prolongee, utilisee pour lutter contre la consommation de substances a mauvais escient |
WO2015089530A1 (fr) * | 2013-12-20 | 2015-06-25 | G.L. PHARMA GmbH | Forme galénique orale à libération retardée contenant de la morphine et de la naloxone |
CA2847781C (fr) * | 2014-03-28 | 2019-03-12 | Purdue Pharma | Reduction de l'appreciation de medicament chez un sujet |
WO2015173195A1 (fr) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol |
EP3148512A1 (fr) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Microparticules protégées contre une libération massive dans l'éthanol |
AU2015284078B2 (en) | 2014-07-03 | 2020-01-30 | SpecGx LLC | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
EP3209282A4 (fr) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Forme galénique anti-abus de remplissage de liquide à libération prolongée |
WO2016170097A1 (fr) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant. |
CA2983640A1 (fr) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Combinaison inviolable de doses fixes permettant la liberation rapide de deux medicaments a partir de particules differentes |
EP3285744A1 (fr) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Combinaison à dose fixe inaltérable présentant une libération rapide de deux médicaments de particules et d'une matrice |
CA2983634A1 (fr) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Combinaison inviolable de doses fixes permettant la liberation rapide de deux medicaments a partir de particules |
JP2018520165A (ja) * | 2015-07-10 | 2018-07-26 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドSun Pharma Advanced Research Company Limited | ヒドロコドンの多数錠剤乱用抵抗性即時放出型固体投薬形態物 |
JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
CA3023800A1 (fr) * | 2016-05-13 | 2017-11-16 | Merck Patent Gmbh | Composition d'extrusion thermofusible utilisant un excipient pour compression directe en tant que plastifiant |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
WO2020068510A1 (fr) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Formes posologiques de capsules à libération immédiate anti-abus |
EP3698776A1 (fr) | 2019-02-19 | 2020-08-26 | Grünenthal GmbH | Forme posologique inviolable à libération immédiate et résistance à l'extraction par solvant |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US6488961B1 (en) | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
DE19740983A1 (de) | 1997-09-18 | 1999-04-08 | Warner Lambert Co N D Ges D St | Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten |
ATE251449T1 (de) | 1999-06-14 | 2003-10-15 | Cosmo Spa | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe |
BR0108379A (pt) | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
KR20040060917A (ko) | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
JP4726414B2 (ja) | 2001-10-15 | 2011-07-20 | フェリング ベスローテン フェンノートシャップ | 潰瘍性大腸炎およびクローン病の治療に使用するための5−アミノサリチル酸を含む医薬組成物の調製方法 |
EP1492506B2 (fr) | 2002-04-05 | 2016-06-29 | Euro-Celtique S.A. | Matrice pour liberation prolongee, constante et independante de composes actifs |
JP5189242B2 (ja) * | 2002-09-23 | 2013-04-24 | アルケルメス ファーマ アイルランド リミテッド | 乱用抵抗性の医薬組成物 |
MXPA05010636A (es) | 2003-04-04 | 2005-12-12 | Pharmacia Corp | Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada. |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
PL1658054T3 (pl) | 2003-08-06 | 2007-11-30 | Gruenenthal Gmbh | Postać aplikacyjna zabezpieczona przed nadużyciem |
GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
AU2006208627B8 (en) | 2005-01-28 | 2009-08-13 | Mundipharma Pty Limited | Alcohol resistant dosage forms |
US20070026025A1 (en) | 2005-04-12 | 2007-02-01 | Aquegel Cosmetics, Llc | Topical ointment and method for making and using same |
WO2007013975A2 (fr) | 2005-07-20 | 2007-02-01 | Pharmorx Inc. | Compositions et procedes destines a controler l'abus de medicaments |
DE102005047561A1 (de) * | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
EP1962808B1 (fr) | 2005-12-14 | 2010-09-29 | F. Hoffmann-La Roche AG | Formule de promédicament contre le vhc |
EP1813276A1 (fr) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Formes de dosage inviolables |
US7799790B2 (en) * | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
EP1935405A1 (fr) | 2006-12-22 | 2008-06-25 | LEK Pharmaceuticals D.D. | Comprimés à désintégration orale |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
GB2447898B (en) | 2007-03-24 | 2011-08-17 | Reckitt Benckiser Healthcare | A tablet having improved stability with at least two actives |
CN102203169B (zh) * | 2008-11-12 | 2013-08-28 | 阿克佐诺贝尔国际涂料股份有限公司 | 窄粒度分布的聚合物分散体 |
DE102009015702A1 (de) | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung |
GB201020895D0 (en) | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
-
2009
- 2009-06-05 GB GBGB0909680.1A patent/GB0909680D0/en not_active Ceased
-
2010
- 2010-06-07 SG SG2011089273A patent/SG176304A1/en unknown
- 2010-06-07 AU AU2010255502A patent/AU2010255502B2/en not_active Ceased
- 2010-06-07 EP EP10725263.7A patent/EP2437729B1/fr active Active
- 2010-06-07 EA EA201171389A patent/EA022801B1/ru not_active IP Right Cessation
- 2010-06-07 NZ NZ596879A patent/NZ596879A/xx not_active IP Right Cessation
- 2010-06-07 BR BRPI1012004A patent/BRPI1012004A2/pt not_active Application Discontinuation
- 2010-06-07 SG SG10201402810XA patent/SG10201402810XA/en unknown
- 2010-06-07 CA CA2764517A patent/CA2764517C/fr not_active Expired - Fee Related
- 2010-06-07 CN CN2010800344131A patent/CN102481260A/zh active Pending
- 2010-06-07 JP JP2012513685A patent/JP5635082B2/ja not_active Expired - Fee Related
- 2010-06-07 MX MX2011012929A patent/MX2011012929A/es active IP Right Grant
- 2010-06-07 KR KR1020127000058A patent/KR101816130B1/ko active IP Right Grant
- 2010-06-07 CN CN201610970584.4A patent/CN106667919A/zh active Pending
- 2010-06-07 MY MYPI2011005869A patent/MY173629A/en unknown
- 2010-06-07 ES ES10725263T patent/ES2713957T3/es active Active
- 2010-06-07 US US13/376,113 patent/US9814679B2/en active Active
- 2010-06-07 WO PCT/GB2010/050948 patent/WO2010140007A2/fr active Application Filing
-
2011
- 2011-12-04 IL IL216748A patent/IL216748A0/en unknown
- 2011-12-14 ZA ZA2011/09221A patent/ZA201109221B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012528845A5 (fr) | ||
HRP20170650T1 (hr) | Dozni oblik otporan na promjene | |
US6194000B1 (en) | Analgesic immediate and controlled release pharmaceutical composition | |
JP4669878B2 (ja) | 慢性閉塞性肺疾患(copd)の治療のためのオピオイド | |
HRP20180068T1 (hr) | Formulacije lijeka s produljenim oslobađanjem | |
KR101043492B1 (ko) | 1일 1회 투여용 옥시코돈 제제 | |
JP5501553B2 (ja) | 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程 | |
EP1348429B1 (fr) | Formulations opioides administrables par voie orale et obtenues par fusion-extrusion | |
JP3280810B2 (ja) | 持効性経口投与オピオイド製剤 | |
PH12018000176A1 (en) | Matrix for sustained invariant and independent release of active compounds | |
RU2010129907A (ru) | Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление | |
JP2013199488A5 (fr) | ||
US20070098795A1 (en) | Pharmaceutical formulation | |
JP2011063627A5 (fr) | ||
DE20220910U1 (de) | Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden | |
CN1741790A (zh) | 缓释制剂及其制备方法 | |
JP2006514988A5 (fr) | ||
JP2003513032A (ja) | 制御放出ヒドロコドン処方 | |
RU2009111588A (ru) | Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств | |
AU2011252040B2 (en) | Manufacturing of active-free granules and tablets comprising the same | |
JP2009545560A5 (fr) | ||
JP2009143964A5 (fr) | ||
JP2008528534A5 (fr) | ||
JP2014532078A5 (fr) | ||
AU2011252041B2 (en) | Combination of active loaded granules with additional actives |